MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag413

Медицинская библиотека · The oncologist · 2026

Hormone Receptor-Positive HER2-Negative Oligometastatic Breast Cancer: prognostic stratification and pattern of progression.

Lacaze Jean-Louis, Cabarrou Bastien, Cassou-Mounat Thibaut, Chira Ciprian, Dalmasso Celine, De Maio Eleonora, Jouve Eva, Korenbaum Clément, Massabeau Carole, Nicolai Vincent, Poumeaud François, Selmes Gabrielle, Ung Mony

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2- OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients.

MATERIALS AND

METHODS

All consecutive patients with HR+/HER2- OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as ≤ 5 metastases. Prognostic factors including biological subtype, anatomical distribution, imaging modality, and LAT were evaluated for overall and progression-free survival (OS, PFS).

RESULTS

Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR]=0.52; 95%CI[0.29-0.91], p=0.0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR = 0.29; 95%CI[0.12-0.73], p=0.008) and PFS (HR = 0.40; 95%CI[0.21-0.77], p=0.0064). After first-line systemic therapy, only 18% developed polymetastatic progression.

CONCLUSION

In HR+/HER2- OMBC, three actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.

Для цитирования: Lacaze Jean-Louis, Cabarrou Bastien, Cassou-Mounat Thibaut, Chira Ciprian, Dalmasso Celine, De Maio Eleonora, Jouve Eva, Korenbaum Clément, Massabeau Carole, Nicolai Vincent, Poumeaud François, Selmes Gabrielle, Ung Mony. Hormone Receptor-Positive HER2-Negative Oligometastatic Breast Cancer: prognostic stratification and pattern of progression.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag413.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.